Opening Asia for Russia

Sinovac Vaccine Induces Effective Immune Response in Children and Adolescents

23.03.2021 48 просмотров

Sinovac has announced the effectiveness of its coronavirus vaccine for children and adolescents.

The coronavirus vaccine, developed by the Chinese pharmaceutical company Sinovac, elicits an effective immune response in children and adolescents aged 3 to 17 years. This was stated by Sinovac researcher Zeng Gang after the developer conducted the first and second phases of clinical trials involving more than 500 minors.

“The level of antibodies that appeared in children and adolescents after vaccination is higher, than in adults and elderly people aged 18 to 59 who participated in the initial and intermediate stages of clinical trials, Zeng Gang quoted the Diyi Caijing portal on Tuesday. “Lower doses can elicit a good humoral immune response among children 3 to 11 years of age, and medium doses of the drug are more effective in children and adolescents 12 to 17 years of age.”

Trial participants received two small doses of the vaccine or a placebo . Preliminary data will be published in a peer-reviewed medical journal, the portal clarifies.

So far, Sinovac has not enrolled minors in phase III clinical trials conducted abroad. There are no official publications of clinical data on vaccination of children and adolescents in the world yet.

Previously, manufacturers of the Russian Sputnik V vaccine and the British vaccine developed by the University of Oxford and the pharmaceutical company AstraZeneca (AstraZeneca) announced plans to test drugs from coronavirus among children. The American company Moderna ("Modern") has already begun the second phase of testing the vaccine against COVID-19 mRNA-1273 on minors.

Новости партнёров